Breast Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Verified date | September 2021 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.
Status | Terminated |
Enrollment | 4509 |
Est. completion date | March 26, 2018 |
Est. primary completion date | August 31, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed, American Joint Committee on Cancer (AJCC) stage II or III breast cancer - High risk of breast cancer recurrence, defined as documented evidence of one or more of the following criteria: i) Biopsy evidence of breast cancer in regional lymph node(s) (LN) (node-positive disease); Nodal micrometastases only are not considered node positive ii) Tumor size > 5 cm (T3) or locally advanced disease (T4) - Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and HER-2 status - Subjects must be receiving or be scheduled to receive standard of care systemic adjuvant or neoadjuvant chemotherapy and/or endocrine therapy and/or HER-2 targeted therapy - For subjects receiving adjuvant therapy only: - subjects must have undergone complete resection of the primary tumor with clean surgical margins, or subjects must have undergone resection of the primary tumor and be scheduled for further treatment of the primary tumor with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization - Time between definitive surgery and randomization must be = 12 weeks. Definitive surgery may include secondary interventions (e.g. to clear inadequate surgical margins) - Subjects with node positive disease must have undergone treatment of axillary LN with curative intent, or subjects must be scheduled for further treatment of regional lymph nodes with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization - Subjects must not have received prior neoadjuvant treatment. Endocrine treatment for less than 30 days prior to surgery is not considered prior neoadjuvant treatment - For subjects receiving neoadjuvant therapy only: - Time between start of neoadjuvant treatment and randomization must be = 8 weeks and subjects must be scheduled to undergo definitive treatment (including surgery and/or radiotherapy) with curative intent within approximately 9 months of starting neoadjuvant treatment - Female subjects with age = 18 years - Subjects with reproductive potential must have a negative pregnancy test within 14 days before randomization - Serum calcium or albumin-adjusted serum calcium = 2.0 mmol/L (8.0 mg/dL) and = 2.9 mmol/L (11.5 mg/dL) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Written informed consent before any study-specific procedure is performed Exclusion Criteria: - Prior or current evidence of any metastatic involvement of any distant site - History of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the current diagnosis - Osteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six months - Any prior or synchronous malignancy (other than breast cancer), except i) Malignancy treated with curative intent and with no evidence of disease for = 5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician ii) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease - Active infection with Hepatitis B virus or Hepatitis C virus - Known infection with human immunodeficiency virus (HIV) - Prior history or current evidence of osteomyelitis/osteonecrosis of the jaw - Active dental or jaw condition which requires oral surgery - Planned invasive dental procedure for the course of the study - Non-healed dental or oral surgery - Use of oral bisphosphonates within the past 1 year - Prior or current IV bisphosphonate administration - Prior administration of denosumab - Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s) - Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment. - Subject is of child bearing potential and is not willing to use, in combination with her partner, 2 highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatment - Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D) - Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures. - Any major medical or psychiatric disorder that in the opinion of the investigator prevent the subject from completing the study or interfere with the interpretation of the study results |
Country | Name | City | State |
---|---|---|---|
Argentina | Research Site | Neuquen | Neuquén |
Argentina | Research Site | Provincia De Santa Fe | Santa Fe |
Argentina | Research Site | Quilmes | Buenos Aires |
Argentina | Research Site | Quilmes | Buenos Aires |
Argentina | Research Site | San Martin | Buenos Aires |
Argentina | Research Site | San Miguel de Tucuman | Tucuman |
Australia | Research Site | Bedford Park | South Australia |
Australia | Research Site | Bentleigh East | Victoria |
Australia | Research Site | Camperdown | New South Wales |
Australia | Research Site | Caringbah | New South Wales |
Australia | Research Site | East Melbourne | Victoria |
Australia | Research Site | Fitzroy | Victoria |
Australia | Research Site | Footscray | Victoria |
Australia | Research Site | Frankston | Victoria |
Australia | Research Site | Heidelberg | Victoria |
Australia | Research Site | Kogarah | New South Wales |
Australia | Research Site | Malvern | Victoria |
Australia | Research Site | Parkville | Victoria |
Australia | Research Site | Perth | Western Australia |
Australia | Research Site | Richmond | Victoria |
Australia | Research Site | Ringwood East | Victoria |
Australia | Research Site | Subiaco | Western Australia |
Australia | Research Site | Tweed Heads | New South Wales |
Australia | Research Site | Wahroonga | New South Wales |
Australia | Research Site | Warrnambool | Victoria |
Australia | Research Site | Wodonga | Victoria |
Belgium | Research Site | Antwerpen | |
Belgium | Research Site | Bonheiden | |
Belgium | Research Site | Brugge | |
Belgium | Research Site | Brussel | |
Belgium | Research Site | Bruxelles | |
Belgium | Research Site | Bruxelles | |
Belgium | Research Site | Edegem | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Hasselt | |
Belgium | Research Site | Kortrijk | |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Liège | |
Belgium | Research Site | Libramont | |
Belgium | Research Site | Namur | |
Belgium | Research Site | Oostende | |
Belgium | Research Site | Ottignies | |
Belgium | Research Site | Sint-Niklaas | |
Belgium | Research Site | Tournai | |
Belgium | Research Site | Wilrijk | |
Belgium | Research Site | Yvoir | |
Brazil | Research Site | Barretos | São Paulo |
Brazil | Research Site | Curitiba | Paraná |
Brazil | Research Site | ItajaÃ- | Santa Catarina |
Brazil | Research Site | Londrina | Paraná |
Brazil | Research Site | Porto Alegre | Rio Grande Do Sul |
Brazil | Research Site | Porto Alegre | Rio Grande Do Sul |
Brazil | Research Site | Porto Alegre | Rio Grande Do Sul |
Brazil | Research Site | São Paulo | |
Brazil | Research Site | São Paulo | |
Brazil | Research Site | Salvador | Bahia |
Brazil | Research Site | Salvador | Bahia |
Brazil | Research Site | Santo Andre | São Paulo |
Brazil | Research Site | Sao Paulo | São Paulo |
Bulgaria | Research Site | Plovdiv | |
Bulgaria | Research Site | Rousse | |
Bulgaria | Research Site | Sofia | |
Bulgaria | Research Site | Sofia | |
Bulgaria | Research Site | Stara Zagora | |
Bulgaria | Research Site | Varna | |
Bulgaria | Research Site | Veliko Tarnovo | |
Canada | Research Site | Barrie | Ontario |
Canada | Research Site | Brampton | Ontario |
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | Edmonton | Alberta |
Canada | Research Site | Greenfield Park | Quebec |
Canada | Research Site | Kelowna | British Columbia |
Canada | Research Site | Kingston | Ontario |
Canada | Research Site | Kitchener | Ontario |
Canada | Research Site | Moncton | New Brunswick |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Ottawa | Ontario |
Canada | Research Site | Quebec | |
Canada | Research Site | Sault Ste. Marie | Ontario |
Canada | Research Site | Sherbrooke | Quebec |
Canada | Research Site | St. John's | Newfoundland and Labrador |
Canada | Research Site | Sudbury | Ontario |
Canada | Research Site | Sydney | Nova Scotia |
Canada | Research Site | Toronto | Ontario |
Canada | Research Site | Toronto | Ontario |
Canada | Research Site | Victoria | British Columbia |
Chile | Research Site | Santiago | |
Chile | Research Site | Temuco | CautÃ-n |
Chile | Research Site | Vina del Mar | ValparaÃ-so |
Czechia | Research Site | Brno | |
Czechia | Research Site | Brno | |
Czechia | Research Site | Chomutov | |
Czechia | Research Site | Horovice | |
Czechia | Research Site | Hradec Kralove | |
Czechia | Research Site | Olomouc | |
Czechia | Research Site | Praha 10 | |
Czechia | Research Site | Praha 10 | |
Czechia | Research Site | Praha 4 | |
Czechia | Research Site | Praha 5 | |
Czechia | Research Site | Praha 8 | |
Denmark | Research Site | Ã…rhus C | |
Denmark | Research Site | Herning | |
Denmark | Research Site | Vejle | |
Denmark | Research Site | Viborg | |
France | Research Site | Angers | |
France | Research Site | Bordeaux Cedex | |
France | Research Site | Dijon | |
France | Research Site | Grenoble | |
France | Research Site | Hyères | |
France | Research Site | Le Mans | |
France | Research Site | Lille | |
France | Research Site | Monaco | |
France | Research Site | Nantes Cedex 2 | |
France | Research Site | Paris | |
France | Research Site | Pierre-Benite | |
France | Research Site | Saint Priest en Jarez Cedex | |
France | Research Site | Strasbourg cedex | |
France | Research Site | Villejuif cedex | |
Germany | Research Site | Berlin | |
Germany | Research Site | Berlin | |
Germany | Research Site | Bonn | |
Germany | Research Site | Bottrop | |
Germany | Research Site | Erlangen | |
Germany | Research Site | Frankfurt | |
Germany | Research Site | Kiel | |
Germany | Research Site | Koblenz | |
Germany | Research Site | München | |
Germany | Research Site | München | |
Germany | Research Site | München | |
Germany | Research Site | Mannheim | |
Germany | Research Site | Recklinghausen | |
Germany | Research Site | Rostock | |
Germany | Research Site | Tübingen | |
Germany | Research Site | Trier | |
Greece | Research Site | Athens | |
Greece | Research Site | Athens | |
Greece | Research Site | Heraklion | |
Greece | Research Site | Patra | |
Greece | Research Site | Thessaloniki | |
Greece | Research Site | Thessaloniki | |
Hong Kong | Research Site | Hong Kong | |
Hong Kong | Research Site | New Territories | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Debrecen | |
Hungary | Research Site | Gyor | |
Hungary | Research Site | Nyiregyhaza | |
Hungary | Research Site | Pecs | |
Hungary | Research Site | Szeged | |
Hungary | Research Site | Szekesfehervar | |
Hungary | Research Site | Szolnok | |
Hungary | Research Site | Zalaegerszeg | |
India | Research Site | Ahmednagar | Maharashtra |
India | Research Site | Aurangabad | Maharashtra |
India | Research Site | Bangalore | Karnataka |
India | Research Site | Chennai | Tamil Nadu |
India | Research Site | Hyderabad | Andhra Pradesh |
India | Research Site | Jaipur | Rajasthan |
India | Research Site | Madurai | Tamil Nadu |
India | Research Site | Miraj | Maharashtra |
India | Research Site | Mumbai | Maharashtra |
India | Research Site | Mumbai | Maharashtra |
India | Research Site | Nashik | Maharashtra |
India | Research Site | Nashik | Maharashtra |
India | Research Site | Pune | Maharashtra |
Ireland | Research Site | Cork | |
Ireland | Research Site | Dublin | |
Ireland | Research Site | Dublin | |
Ireland | Research Site | Dublin | |
Ireland | Research Site | Limerick | |
Ireland | Research Site | Waterford | |
Israel | Research Site | Ashkelon | |
Israel | Research Site | Haifa | |
Israel | Research Site | Jerusalem | |
Israel | Research Site | Kfar Sava | |
Israel | Research Site | Petah Tikva | |
Israel | Research Site | Poria Eylit | |
Israel | Research Site | Rehovot | |
Israel | Research Site | Tel Aviv | |
Israel | Research Site | Tel Aviv | |
Italy | Research Site | Ancona | |
Italy | Research Site | Bari | |
Italy | Research Site | Brescia | |
Italy | Research Site | Meldola FC | |
Italy | Research Site | Milano | |
Italy | Research Site | Monza (MB) | |
Italy | Research Site | Palermo | |
Italy | Research Site | Parma | |
Italy | Research Site | San Giovanni Rotondo FG | |
Italy | Research Site | Treviglio (BG) | |
Italy | Research Site | Varese | |
Japan | Research Site | Akashi-shi | Hyogo |
Japan | Research Site | Chuo-ku | Tokyo |
Japan | Research Site | Fukuoka-shi | Fukuoka |
Japan | Research Site | Hidaka-Shi | Saitama |
Japan | Research Site | Isehara-shi | Kanagawa |
Japan | Research Site | Kagoshima-shi | Kagoshima |
Japan | Research Site | Kitaadachi-gun | Saitama |
Japan | Research Site | Kitakyushu-shi | Fukuoka |
Japan | Research Site | Kumamoto-shi | Kumamoto |
Japan | Research Site | Kurashiki-shi | Okayama |
Japan | Research Site | Kure-shi | Hiroshima |
Japan | Research Site | Kurume-shi | Fukuoka |
Japan | Research Site | Kyoto-shi | Kyoto |
Japan | Research Site | Matsuyama-shi | Ehime |
Japan | Research Site | Miyazaki-shi | Miyazaki |
Japan | Research Site | Nagoya-shi | Aichi |
Japan | Research Site | Nagoya-shi | Aichi |
Japan | Research Site | Niigata-shi | Niigata |
Japan | Research Site | Osaka-shi | Osaka |
Japan | Research Site | Osaka-shi | Osaka |
Japan | Research Site | Shimotsuke-shi | Tochigi |
Japan | Research Site | Suita-shi | Osaka |
Japan | Research Site | Suntou-gun | Shizuoka |
Japan | Research Site | Tokyo | |
Japan | Research Site | Tokyo | |
Japan | Research Site | Tokyo | |
Japan | Research Site | Tokyo | |
Japan | Research Site | Utsunomiya-shi | Tochigi |
Korea, Republic of | Research Site | Goyang-si, Gyeonggi-do | |
Korea, Republic of | Research Site | Incheon | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Latvia | Research Site | Daugavpils | |
Latvia | Research Site | Liepaja | |
Latvia | Research Site | Riga | |
Malaysia | Research Site | Kota Bharu | Kelantan |
Malaysia | Research Site | Kuala Lumpur | Wilayah Persekutuan |
Malaysia | Research Site | Kuala Lumpur | Wilayah Persekutuan |
Malaysia | Research Site | Subang Jaya | Selangor (incl. Putrajaya) |
Mexico | Research Site | Colima | |
Mexico | Research Site | Distrito Federal | |
Mexico | Research Site | Durango | |
Mexico | Research Site | Leon | Guanajuato |
Mexico | Research Site | Mexico | Distrito Federal |
Mexico | Research Site | Mexico City | Distrito Federal |
Mexico | Research Site | Mexico City | Distrito Federal |
Mexico | Research Site | Monterrey | Nuevo León |
Mexico | Research Site | Pachuca de Soto | Hidalgo |
Mexico | Research Site | Queretaro | Querétaro |
Mexico | Research Site | San Luis Potosi | San Luis PotosÃ- |
Mexico | Research Site | Toluca | |
Netherlands | Research Site | Amsterdam | |
Netherlands | Research Site | Bergen op Zoom | |
Netherlands | Research Site | Breda | |
Netherlands | Research Site | Capelle aan den ijssel | |
Netherlands | Research Site | Den Haag | |
Netherlands | Research Site | Dordrecht | |
Netherlands | Research Site | Hoofddorp | |
Netherlands | Research Site | Leiden | |
Netherlands | Research Site | Nieuwegein | |
Netherlands | Research Site | Rotterdam | |
Netherlands | Research Site | Rotterdam | |
Netherlands | Research Site | Schiedam | |
Netherlands | Research Site | Sittard-Geleen | |
Netherlands | Research Site | Tiel | |
Netherlands | Research Site | Tilburg | |
Netherlands | Research Site | Venlo | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Peru | Research Site | Lima | |
Philippines | Research Site | Cebu City | |
Philippines | Research Site | Manila | |
Philippines | Research Site | Manila | |
Philippines | Research Site | Metro Manila | |
Philippines | Research Site | Quezon City | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Krakow | |
Poland | Research Site | Olsztyn | |
Poland | Research Site | Poznan | |
Poland | Research Site | Rzeszow | |
Poland | Research Site | Szczecin | |
Portugal | Research Site | Lisboa | |
Portugal | Research Site | Lisboa | |
Portugal | Research Site | Porto | |
Portugal | Research Site | Porto | |
Portugal | Research Site | Santa Maria da Feira | |
Romania | Research Site | Bucharest | |
Romania | Research Site | Craiova | |
Romania | Research Site | Sibiu | |
Romania | Research Site | Suceava | |
Romania | Research Site | Timisoara | |
Russian Federation | Research Site | Barnaul | |
Russian Federation | Research Site | Chelyabinsk | |
Russian Federation | Research Site | Ivanovo | |
Russian Federation | Research Site | Kazan | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Saint Petersburg | |
Russian Federation | Research Site | Saint Petersburg | |
Serbia | Research Site | Belgrade | |
Serbia | Research Site | Nis | |
Slovakia | Research Site | Bardejov | |
Slovakia | Research Site | Kosice | |
Slovakia | Research Site | Michalovce | |
Slovakia | Research Site | Poprad | |
Slovakia | Research Site | Presov | |
Slovakia | Research Site | Spisska Nova Ves | |
Slovakia | Research Site | Trebisov | |
Slovenia | Research Site | Ljublijana | |
Slovenia | Research Site | Maribor | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Groenkloof | Gauteng |
South Africa | Research Site | Johannesburg | Gauteng |
South Africa | Research Site | Pietermaritzburg | |
South Africa | Research Site | Port Elizabeth | |
South Africa | Research Site | Pretoria | |
South Africa | Research Site | Pretoria | |
Spain | Research Site | A Coruña | Galicia |
Spain | Research Site | A Coruña | Galicia |
Spain | Research Site | Alcorcón | Madrid |
Spain | Research Site | Badalona | Cataluña |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Cádiz | AndalucÃ-a |
Spain | Research Site | Córdoba | AndalucÃ-a |
Spain | Research Site | Elche | Comunidad Valenciana |
Spain | Research Site | Girona | Cataluña |
Spain | Research Site | Jaén | AndalucÃ-a |
Spain | Research Site | Lleida | Cataluña |
Spain | Research Site | Málaga | AndalucÃ-a |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Spain | Research Site | Sabadell | Cataluña |
Spain | Research Site | Santander | Cantabria |
Spain | Research Site | Sevilla | AndalucÃ-a |
Spain | Research Site | Valencia | Comunidad Valenciana |
Spain | Research Site | Valencia | Comunidad Valenciana |
Spain | Research Site | Zaragoza | Aragón |
Taiwan | Research Site | Keelung City | Keelung |
Taiwan | Research Site | Putzu City | Chiayi |
Taiwan | Research Site | Tainan | |
Taiwan | Research Site | Taipei | |
Turkey | Research Site | Ä°zmir | |
Turkey | Research Site | Ankara | |
Turkey | Research Site | Ankara | |
Turkey | Research Site | Bornova-Izmir | |
United Kingdom | Research Site | Bebington | |
United Kingdom | Research Site | Birmingham | |
United Kingdom | Research Site | Brighton | |
United Kingdom | Research Site | Bristol | |
United Kingdom | Research Site | Cambridge | |
United Kingdom | Research Site | Dorset | |
United Kingdom | Research Site | Guildford | |
United Kingdom | Research Site | Leeds | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Newcastle | |
United Kingdom | Research Site | Peterborough | |
United Kingdom | Research Site | Plymouth | |
United Kingdom | Research Site | Poole | |
United Kingdom | Research Site | Portsmouth | |
United Kingdom | Research Site | Sheffield | |
United Kingdom | Research Site | Truro | |
United States | Research Site | Abilene | Texas |
United States | Research Site | Alhambra | California |
United States | Research Site | Anaheim | California |
United States | Research Site | Ann Arbor | Michigan |
United States | Research Site | Annapolis | Maryland |
United States | Research Site | Asheville | North Carolina |
United States | Research Site | Athens | Georgia |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Bethesda | Maryland |
United States | Research Site | Beverly Hills | California |
United States | Research Site | Birmingham | Alabama |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Boynton Beach | Florida |
United States | Research Site | Campbell | California |
United States | Research Site | Cedar Rapids | Iowa |
United States | Research Site | Charleston | South Carolina |
United States | Research Site | Chattanooga | Tennessee |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Columbia | South Carolina |
United States | Research Site | Columbia | Maryland |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Coral Springs | Florida |
United States | Research Site | Corpus Christi | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Danvers | Massachusetts |
United States | Research Site | Denver | Colorado |
United States | Research Site | Denville | New Jersey |
United States | Research Site | Detroit | Michigan |
United States | Research Site | East Setauket | New York |
United States | Research Site | Edina | Minnesota |
United States | Research Site | El Paso | Texas |
United States | Research Site | Fort Lauderdale | Florida |
United States | Research Site | Fresno | California |
United States | Research Site | Fullerton | California |
United States | Research Site | Garland | Texas |
United States | Research Site | Germantown | Tennessee |
United States | Research Site | Grand Junction | Colorado |
United States | Research Site | Hackensack | New Jersey |
United States | Research Site | Henderson | Nevada |
United States | Research Site | Hershey | Pennsylvania |
United States | Research Site | High Point | North Carolina |
United States | Research Site | Hilton Head Island | South Carolina |
United States | Research Site | Hollywood | Florida |
United States | Research Site | Houston | Texas |
United States | Research Site | Houston | Texas |
United States | Research Site | Hutchinson | Kansas |
United States | Research Site | Indianapolis | Indiana |
United States | Research Site | Jackson | Mississippi |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Jefferson City | Missouri |
United States | Research Site | Jonesboro | Arkansas |
United States | Research Site | La Verne | California |
United States | Research Site | Lancaster | California |
United States | Research Site | Lebanon | New Hampshire |
United States | Research Site | Lincoln | Nebraska |
United States | Research Site | Long Beach | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Melbourne | Florida |
United States | Research Site | Minneapolis | Minnesota |
United States | Research Site | Nashville | Tennessee |
United States | Research Site | New Haven | Connecticut |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | Niles | Illinois |
United States | Research Site | Northridge | California |
United States | Research Site | Nyack | New York |
United States | Research Site | Paducah | Kentucky |
United States | Research Site | Pawtucket | Rhode Island |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Plano | Texas |
United States | Research Site | Redondo Beach | California |
United States | Research Site | Richlands | Virginia |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Roanoke | Virginia |
United States | Research Site | Saint Louis Park | Minnesota |
United States | Research Site | San Antonio | Texas |
United States | Research Site | San Antonio | Texas |
United States | Research Site | Santa Barbara | California |
United States | Research Site | Santa Maria | California |
United States | Research Site | Seattle | Washington |
United States | Research Site | Seattle | Washington |
United States | Research Site | Sioux Falls | South Dakota |
United States | Research Site | Tacoma | Washington |
United States | Research Site | Torrance | California |
United States | Research Site | Tucson | Arizona |
United States | Research Site | Tulsa | Oklahoma |
United States | Research Site | Tyler | Texas |
United States | Research Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Amgen | Daiichi Sankyo, Inc. |
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Turkey, United Kingdom,
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2. — View Citation
Coleman R, Zhou Y, Jandial D, Cadieux B, Chan A. Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Adv Ther. 2021 Aug;38(8):4569-4580. doi: 10.1007/s12325-021-01812-9. Epub 2021 Jun 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone Metastasis-free Survival (BMFS) | BMFS time was defined as the time interval from the randomization date to the first occurrence of bone metastasis or death from any cause, whichever came first. Participants last known to be alive with no bone metastasis were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first occurrence of bone metastasis before randomization were censored at their randomization date.
Bone metastasis must have been confirmed by central imaging analysis or by biopsy, Evidence of disseminated tumor cells in bone marrow was not sufficient for determination of disease recurrence. Development of new primary malignancy in bone was not considered as bone metastasis. Since the median BMSF time could not be estimated due to low number of events, the percentage of participants with an event (i.e., bone metastasis or death) is reported. |
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively. | |
Secondary | Disease-free Survival (DFS) | DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date.
Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported. |
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively. | |
Secondary | Disease-free Survival (DFS) in the Postmenopausal Subset | DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date.
Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence. Since the median DFS time in the postmenopausal subset could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported. |
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively. | |
Secondary | Overall Survival | Overall survival (OS) time was defined as the time interval from the randomization date to the date of death from any cause. Participants last known to be alive were censored at their last contact date.
Since the median time to overall survival could not be estimated at the time of the final analysis due to low numbers of events, the percentage of participants with an event (i.e., death) is reported. |
From randomization until the end of study; median (minimum, maximum) time on study was 72.7 (0, 92) and 72.3 (0, 92) months in each treatment group respectively. | |
Secondary | Distant Recurrence-free Survival | Distant recurrence-free survival (DRFS) was defined as the time interval from the randomization date to the date of first observation of distant disease recurrence or death from any cause, whichever came first. Participants last known to be alive, who had not experienced distant disease recurrence, were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first distant recurrence before randomization were censored at their randomization date.
Distant disease recurrence includes confirmed bone metastasis and extraosseous disease other than local-regional disease recurrence. Development of non-breast cancer new primary malignancy was not considered as distant disease recurrence. Since the median time to DRFS could not be estimated due to the low number of events, the percentage of participants with an event (i.e., distant recurrence or death) is reported. |
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |